HomeFileStructural heart disease

Structural heart disease

SCOPE I: Acurate NEO vs Sapien 3, no non-inferiority at one year?

The randomized controlled study SCOPE 1 failed to show significant differences at one year between the self-expandable...

Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis

Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with...

High Deployment: Also Trending with Balloon Expandable Valves

Conventional implantation of balloon expandable SAPIEN-3 results in a final 70:30 or 80:20 ratio of the valve...

Cusp Overlap for Higher CoreValve Implantation

Implant depth greater than the length of the membranous septum is an independent predictor of permanent pacemaker...

Five-Years After PFO Closure: Procedural Safety and Effectiveness

Five-year outcomes of the randomized REDUCE study showed a continuous benefit from patent foramen ovale (PFO) closure...

TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.

At two-year followup, primary end point continued to be significantly lower with Sapien 3 vs. conventional surgery,...

Bulletin 116 ProEducar | Percutaneous Closure of Patent Foramen Ovale

A new edition of the ProEducar Educational Bulletin has arrived for Fellows and interventionists in training. On...

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are...